


Afatinib fatinib	————————————————————————————————————	> 1.0 (0.028, 37.) > 1.0 (0.0050, 2.0e+02) NA > 1.0 (0.030, 56.) > 2.3e-18 (1.7e-44, 3.0e+6 5.0e-95 (2.6e-224, 0.025) NA 4.5e-15 (3.6e-37, 0.10) - 2.1 (0.22, 20.)
fatinib	————————————————————————————————————	→ 1.0 (0.0050, 2.0e+02) NA → 1.0 (0.030, 56.) → 2.3e-18 (1.7e-44, 3.0e+05.0e-95 (2.6e-224, 0.025) NA 4.5e-15 (3.6e-37, 0.10) → 2.1 (0.22, 20.)
I)	<	→ 2.3e–18 (1.7e–44, 3.0e+6 5.0e–95 (2.6e–224, 0.025 NA 4.5e–15 (3.6e–37, 0.10) → 2.1 (0.22, 20.)
,	<	5.0e-95 (2.6e-224, 0.025 NA 4.5e-15 (3.6e-37, 0.10)
nib		` ' '
		` · · · · · · · · · · · · · · · · · · ·
52.7% I) 5.5%	(1.2e+11 (1.2e-05, 1.3e+2) 4.6 (0.20, 6.4e+02) 1.0 (0.36, 3.0) 1.1 (0.45, 3.5)
l) 0.0%	←	1.0 (0.48, 2.0) 0.98 (0.016, 64.) 1.1 (0.42, 2.9) 1.1 (0.50, 3.3)
d) 0.0%	······• •	1.0 (0.30, 3.3) 1.0 (0.015, 67.) 0.78 (0.26, 2.3) 0.80 (0.28, 2.3)
1	5.5%) 0.0%) 0.0% — — — — — — — — — — — — — — — — — — —








Study	I^2		Odds Ratio (95% Crl)
Erlotinib vs Dacomitinib			,
59 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		1.3 (0.58, 2.8) 1.3 (0.020, 83.) 1.8 (0.57, 5.9) 1.8 (0.66, 6.3)
Gefitinib vs Dacomitinib			
43 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		0.98 (0.030, 32.) 0.97 (0.0044, 2.2e+02) 1.3 (0.34, 5.0) 1.3 (0.34, 4.7)
Placebo vs Dacomitinib			
r6 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	15.2%		2.6 (0.64, 10.) 2.7 (0.036, 1.9e+02) 1.1 (0.34, 3.7) 1.2 (0.38, 3.8)
Erlotinib vs DHFRi			
r18 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		← → ← → ← → ← ← ← ← ← ← ← ← ← ← ← ← ← ←	1.3 (0.26, 6.9) 1.4 (0.018, 1.1e+02) NA 1.3 (0.18, 10.)
antiangio vs Erlotinib_			
antiangio 37 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		2.4e+27 (3.5e-27, 1.6e+81) 4.4e+31 (7.0e-16, 1.5e+82) 6.4 (1.4, 29.) 6.5 (2.0, 41.)
			-



1.1 (0.48, 2.4) 2.6e-18 (2.2e-44, 3.2e+08) 7 0.89 (0.30, 7.6) NA 1.1 (0.35, 2.7)	Study	I^2			Odds Ratio (95% Crl)
39 7 Pooled (pair-wise) 17.8% Indirect (back-calculated) Pooled (network) 0.0% Erlotinib_MMPi vs Erlotinib 21 Pooled (pair-wise)	Erlotinib_METi vs Erlotin	nib			
Erlotinib_MMPi vs Erlotinib 21 Pooled (pair-wise) Indirect (back-calculated) Pooled (network) Erlotinib_antiangio vs Erlotinib 15 16	39 7 Pooled (pair–wise) Indirect (back–calculated)		< <u>-</u>	- - - -	2.6e-18 (2.2e-44, 3.2e+08) 1.3 (0.46, 3.6) 0.89 (0.030, 7.6) NA
21	,				1.1 (0.33, 2.1)
15 16 2 31 32 32 34 35 36 37 41 Pooled (pair-wise) 0.22 (0.013, 3.5) 6.7e+11 (0.00017, 2.7e+27) 9 1.9e-18 (1.1e-44, 3.4e+08) 9 1.2e-18 (1.1e-44, 1.3e+08) 9 1.2 (0.54, 2.5) 9 1.0 (0.11, 10.) 9 1.0e-09 (2.5e-51, 4.4e+32) 9 1.3 (0.17, 5.0)	21 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)		<	\longrightarrow	8.8e+15 (8.8, 1.4e+76) NA
16	_	lotinib			
Pooled (network) 25.3% 1.4 (0.66, 2.6)	16 2 25 33 34 35 36 37 41 Pooled (pair–wise) Indirect (back–calculated)				6.7e+11 (0.00017, 2.7e+27) 1.9e-18 (1.1e-44, 3.4e+08) 1.7 (0.74, 4.1) 1.2e-18 (1.1e-44, 1.3e+08) 1.2 (0.54, 2.5) 2.6e+13 (3.2e-05, 2.2e+31) 1.0 (0.11, 10.) 1.0e-09 (2.5e-51, 4.4e+32) 2.5e-18 (1.8e-44, 3.4e+08) 1.3 (0.17, 5.0) NA 1.4 (0.66, 2.6)







Study **I**^2 Odds Ratio (95% Crl) **Placebo vs Osimertinib** 0.55 (0.21, 1.4) 10 → 8.2e-19 (7.6e-45, 8.9e+07) r19 Pooled (pair-wise) 71.4% 0.29 (0.0025, 3.5) Indirect (back-calculated) 0.41 (0.12, 1.4) Pooled (network) 10.6% 0.39 (0.11, 1.1) 0.03 30